MiniMed Group, Inc. (MMED) Stock Analysis
Healthcare · Medical Instruments & Supplies · NasdaqGS
MiniMed Group, Inc. (MMED) posted $2.71B in revenue for fiscal 2025 (up 10.0% year over year), with a net loss of $250.00M, and has compounded revenue about 10.0%/yr over five years, per its SEC filings.
Data last refreshed August 2, 2026 from SEC filings · how we compute this
The analyst's take on MiniMed Group, Inc.
MiniMed Group, Inc. has grown revenue from $2.25B to $2.71B over the last 3 fiscal years, compounding about 10% a year. The most recent year was up 10%, roughly in line with its longer-run pace.
Net margin sits at -9.2%, down 4.7 points year over year on a 56.2% gross margin.
The one thing worth a second look in the filings is currently unprofitable.
Synthesised from MiniMed Group, Inc.'s SEC filings — descriptive, not advice. Ask the analyst your own question →
MiniMed Group, Inc. revenue & earnings — last 3 fiscal years
| Metric | 2023 | 2024 | 2025 |
|---|---|---|---|
| Revenue | $2.25B | $2.47B | $2.71B |
| Gross profit | $1.31B | $1.44B | $1.52B |
| Net income | $-96.00M | $-112.00M | $-250.00M |
| Net margin | -4.3% | -4.5% | -9.2% |
Source: MiniMed Group, Inc. SEC filings (10-K).
MiniMed Group, Inc.: 1 potential red flag in the filings
Patterns in the filed statements worth a second look — computed and cited, not AI guesswork, and not a signal to sell. The kind of thing that hides in a 10-K.
- Currently unprofitableThe latest fiscal year was a net loss (net margin -9.2%).
Explore 3 years of MiniMed Group, Inc. financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track MMED in your portfolio →
MiniMed Group, Inc. financial history by metric
About MiniMed Group, Inc.
MiniMed Group, Inc. operates as a medical technology company that develops, manufactures, and markets medical equipment for the management of diabetes. The company offers technologies including insulin delivery devices, including insulin pumps and pens, continuous glucose monitors, other consumables, supplies, and related software and services. It serves people with diabetes who require insulin therapy, which represents all people with T1D and a subset of those with T2D. The company's platform includes Automated Insulin Delivery (AID) systems for glucose sensing and automated insulin dosing and administration for glycemic control and Smart Multiple Daily Injection (MDI) systems for self-administering insulin by manual injections, which include InPen, Simplera, or Guardian 4, and wraparound applications and services. MiniMed Group, Inc. was founded in 1983 and is headquartered in Northridge, California.
MiniMed Group, Inc. — frequently asked questions
What is MiniMed Group, Inc.'s revenue?
MiniMed Group, Inc. (MMED) reported revenue of $2.71B for fiscal year 2025, up 10.0% from the prior year, according to its SEC filings.
Is MiniMed Group, Inc. profitable?
No — MMED reported a net loss of $-250.00M in fiscal 2025.
What is MMED's P/E ratio?
MiniMed Group, Inc. trades at a price-to-earnings ratio of about 0.0 based on the latest data in our nightly-refreshed cache.
How fast is MiniMed Group, Inc. growing?
MMED's revenue grew at roughly 10.0% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
How much debt does MiniMed Group, Inc. have?
As of fiscal year 2025, MMED carried roughly $0 in total debt (short- plus long-term borrowings), per its filed balance sheet.
What is MiniMed Group, Inc.'s gross margin?
MMED's gross margin was 56.2% in fiscal 2025 — gross profit of $1.52B on revenue of $2.71B.
What is MiniMed Group, Inc.'s market cap?
MiniMed Group, Inc. (MMED) has a market capitalization of about $4.26B, based on the latest data in our nightly-refreshed cache.
When does MiniMed Group, Inc.'s fiscal year end?
MMED's fiscal year ends in April. Its most recent annual filing covers the fiscal year ending 2025-04-30.
Where does this data come from?
All figures are computed from MiniMed Group, Inc.'s official SEC filings (10-K and 10-Q), covering 3 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.